Effects of pertussis vaccination on transmission: vaccine efficacy for infectiousness.

We estimated the effect of pertussis vaccination on reducing transmission from vaccinated breakthrough cases from a comprehensive follow-up of a community of 30,000 residents in Niakhar, Senegal. Using a wide spectrum of case definitions, vaccine efficacy was estimated as 1 - the ratio of secondary attack rates (SAR) in all households with cases during the calendar year 1993, a pertussis epidemic year. Vaccine efficacy for infectiousness (VEi) was 85% (95% confidence interval (CI), 46-95%) for children vaccinated with three doses of a whole-cell (WC; 94%) or an acellullar (6%) pertussis vaccine, with pertussis defined as a cough >/=21 days with paroxysms confirmed by culture, serology, or contact with a culture-confirmed person. It was high for all case definitions. Partial vaccination reduced infectiousness. Pertussis vaccination is highly effective in reducing transmission from vaccinated breakthrough cases.

[1]  K. Forsyth,et al.  Recommendations are needed for adolescent and adult pertussis immunisation: rationale and strategies for consideration. , 2001, Vaccine.

[2]  Pertussis--United States, 1997-2000. , 2002, MMWR. Morbidity and mortality weekly report.

[3]  W. Blackwelder,et al.  A placebo-controlled trial of a pertussis-toxoid vaccine. , 1995, The New England journal of medicine.

[4]  S. Zeger,et al.  Longitudinal data analysis using generalized linear models , 1986 .

[5]  P. Fine,et al.  REFLECTIONS ON THE EFFICACY OF PERTUSSIS VACCINES , 1988 .

[6]  R. Parton.  Review of the biology of Bordetella pertussis. , 1999, Biologicals : journal of the International Association of Biological Standardization.

[7]  P Cantrelle,et al.  Three decades of research on population and health: the ORSTOM experience in rural Senegal: 1962-1991. , 1991 .

[8]  H. Hallander,et al.  A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. , 1996, The New England journal of medicine.

[9]  H. Schmitt,et al.  Pertussis in adults: frequency of transmission after household exposure , 1995, The Lancet.

[10]  H. Hallander.  Microbiological and serological diagnosis of pertussis. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  K. Edwards,et al.  Acellular pertussis vaccines--a solution to the pertussis problem? , 1993, The Journal of infectious diseases.

[12]  Steven G F Wassilak,et al.  Epidemiology of pertussis in a West African community before and after introduction of a widespread vaccination program. , 2002, American journal of epidemiology.

[13]  Ulrich Heininger,et al.  A Comparative Efficacy Trial in Germany in Infants Who Received Either the Lederle/Takeda Acellular Pertussis Component DTP (DTaP) Vaccine, the Lederle Whole-Cell Component DTP Vaccine, or DT Vaccine , 1998, Pediatrics.

[14]  J. Cherry,et al.  The Effect of Investigator Compliance (Observer Bias) on Calculated Efficacy in a Pertussis Vaccine Trial , 1998, Pediatrics.

[15]  M. Diehn,et al.  Comparing functional genomic datasets: lessons from DNA microarray analyses of host-pathogen interactions. , 2001, Current opinion in microbiology.

[16]  N. Gay,et al.  Epidemiological determinants of pertussis. , 1997, Developments in biological standardization.

[17]  J. Robbins,et al.  Mass vaccination of children with pertussis toxoid--decreased incidence in both vaccinated and nonvaccinated persons. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  D Greco,et al.  A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. , 1996, The New England journal of medicine.

[19]  D. Heymann.  Control of Communicable Diseases Manual , 2004 .

[20]  John B. Shoven,et al.  I , Edinburgh Medical and Surgical Journal.

[21]  H. Whittle,et al.  Divergent mortality for male and female recipients of low-titer and high-titer measles vaccines in rural Senegal. , 1993, American journal of epidemiology.

[22]  F. Simondon,et al.  Evaluation of an Immunoglobulin G Enzyme-Linked Immunosorbent Assay for Pertussis Toxin and Filamentous Hemagglutinin in Diagnosis of Pertussis in Senegal , 1998, Clinical Diagnostic Laboratory Immunology.

[23]  M E Halloran,et al.  Study designs for evaluating different efficacy and effectiveness aspects of vaccines. , 1997, American journal of epidemiology.

[24]  R. Schneerson,et al.  Immunization of children with pertussis toxoid decreases spread of pertussis within the family. , 1998, The Pediatric infectious disease journal.

[25]  G. Eldering,et al.  A STUDY IN ACTIVE IMMUNIZATION AGAINST PERTUSSIS , 1939 .

[26]  B. Housset,et al.  Role of Adhesins and Toxins in Invasion of Human Tracheal Epithelial Cells by Bordetella pertussis , 2000, Infection and Immunity.

[27]  M. Gahr,et al.  Efficacy of acellular pertussis vaccine in early childhood after household exposure. , 1996, JAMA.

[28]  J. Nelson.  The changing epidemiology of pertussis in young infants. The role of adults as reservoirs of infection. , 1978, American journal of diseases of children.

[29]  Pejman Rohani,et al.  Impact of immunisation on pertussis transmission in England and Wales , 2000, The Lancet.

[30]  W. Orenstein.  Pertussis in adults: epidemiology, signs, symptoms, and implications for vaccination. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  Robert Tibshirani,et al.  An Introduction to the Bootstrap , 1994 .

[32]  P. Fine,et al.  THE RECURRENCE OF WHOOPING COUGH: POSSIBLE IMPLICATIONS FOR ASSESSMENT OF VACCINE EFFICACY , 1982, The Lancet.

[33]  R. Schneerson,et al.  A toxoid vaccine for pertussis as well as diphtheria? Lessons to be relearned , 1996, The Lancet.

[34]  F. Simondon,et al.  Practical experiences in obtaining informed consent for a vaccine trial in rural Africa. , 1997, The New England journal of medicine.

[35]  S. Mboup,et al.  A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. , 1997, Vaccine.

[36]  Haitao Chu,et al.  Estimating Vaccine Efficacy From Secondary Attack Rates , 2003 .

[37]  J. Cherry.  Pertussis in the preantibiotic and prevaccine era, with emphasis on adult pertussis. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.